ClinicalTrials.gg
SuspendedNCT07190885Updated Sep 23, 2026

A Pharmacokinetic Study of YN001 in Healthy Participants

A Phase 1 interventional study of YN001 in Healthy Volunteers, sponsored by Beijing Inno Medicine Co., Ltd.. Suspended at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Beijing Inno Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was suspended
The study was suspended at the request of the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.

Read the detailed description

This will be a single center, open-label, single dose study in Healthy volunteers.

A total of approximately 24 healthy male and female participants will be enrolled into two dose groups (12 participants per dose group).

The study will consist of a maximum 27-day screening period, a baseline period (Day -1), a treatment period (Day 1), a follow up period (Day 2-15). After completion of relevant assessments on Day 8, participants will be followed for an additional 7 days and will have a completion visit conducted via phone call on Day 15.

The study is designed to refine PK profile of YN001 in Australian healthy volunteers to support further clinical development of YN001.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Beijing Inno Medicine Co., Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed.
  2. Healthy male and female adults aged from 18 to 65 years of age (inclusive) at time of Screening, and in good health as determined by no (as judged by the PI/delegate) past medical history, physical examination, and vital signs, (ECG), and laboratory tests at Screening and Baseline (Day -1).
  3. Vital signs (systolic and diastolic blood pressure and pulse rate) measurements within the below ranges at Screening and Baseline (Day -1):

    • tympanic body temperature between 35.5-37.7 °C
    • systolic blood pressure, 90-140 mm Hg (inclusive)
    • diastolic blood pressure, 40-95 mm Hg (inclusive)
    • pulse rate, 40-100 bpm (inclusive)
  4. Weigh at least 50 kg and have a (BMI) within the range of 18-32 kg/m2 at Screening and Baseline (Day -1).
  5. Meets requirements.
  6. Willing and able to comply with the study requirements and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Received an agent within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
  2. Use of any prescription drugs, over the counter (OTC) medication, herbal supplements, dietary supplements (vitamins included), any type of vaccine within two weeks prior to the study drug administration, unless deemed acceptable by the Principal Investigator (or delegate) and agreement with the Sponsor.
  3. Fasting triglyceride concentration >2.8 mmol/L at Screening or Baseline (Day -1).
  4. A history of abnormalities, or any ECG abnormalities at Screening or Baseline (Day -1).
  5. Pregnant or nursing (lactating) women.
  6. Average use of more than 5 cigarettes or equivalent nicotine containing products per week and/or unwilling to abstain from such products 7 days prior to study administration through until Day 15. Positive urine cotinine test at Baseline (Day -1); repeat testing may be permitted at PI/delegate discretion.
  7. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by positive results for alcohol or drugs conducted at Screening and/or Baseline (Day -1). Alcohol abuse is defined as consumption of 14 or more standard drinks per week (where 1 unit = 375 mL of beer [3.5% alc/vol], 30 mL of 40% spirit or a 100 mL glass of wine [13%]). Any THC-containing products should not be used at least 7 days prior to Screening through until completion of Day 15.
  8. A positive surface antigen (HBsAg), or positive virus (HCV) or (HIV) test result at Screening.
  9. History of myopathy/myalgia, or susceptible to myopathy/rhabdomyolysis (e.g., hypothyroidism, family history of hereditary myopathy, previous muscle toxicity with HMG CoA reductase inhibitors or fibrates).
  10. Multiple drug allergies, or history of allergic reactions to study drug or any components of the study drug.
  11. Donation or loss of more than 400 ml of blood within 3 months prior to study drug administration.
  12. Plasma donation (> 100 ml) within 60 days prior to first dosing.
  13. levels below 120 g/L at Screening or Baseline (Day -1).
  14. Recent (within the last 3 years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.).
  15. Recent (within the last 3 years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and , treated or not treated), or cardiac dysfunction or myocardial infarction.
  16. History of significant food allergies (e.g. anaphylactic reactions). Mild (non-anaphylactic, ) food allergies such as lactose intolerance/glucose intolerance are permitted.
  17. Any surgical or medical condition which might significantly alter the distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in case of participation in the study. The Investigator should make this determination in consideration of the participant's medical history and/or clinical or laboratory evidence of any of the following:

    1. Inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding in the last 6 months.
    2. Pancreatic injury or pancreatitis in the last 6 months.
    3. Liver disease or liver injury as indicated by abnormal liver function tests at Screening or Baseline (Day -1) such as (AST), SGPT (ALT), GGT, alkaline phosphatase (ALP), or total . The Investigator should be guided by the following criteria:

      • Any single parameter of ALT, AST, GGT, ALP, or total bilirubin must not exceed 1.5 x (ULN).
    4. History or presence of impaired renal function as indicated by abnormal creatinine and/or urea values (e.g., \<90 mL/min/1.73 m2 (calculated by CKD-EPI equation), or abnormal urinary constituents (e.g., albuminuria), deemed clinically significant by the PI/delegate at Screening or Baseline (Day -1).
    5. Evidence of urinary obstruction or difficulty in voiding at Screening.
  18. Significant illness resolved within two weeks prior to dosing, which may affect the study drug administration and safety assessments in the opinion of the PI/delegate.
  19. Any other medical condition or social circumstance, which in the opinion of the PI/delegate would impede compliance with or hinder completion of the study or otherwise deem the participant unsuitable for inclusion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    YN001

    Approximately 24 healthy male and female volunteers (18-65 years) will receive a single dose of YN001. Participants will be assigned to one of two dose cohorts: Cohort 1 - 20 mg (n=12) or Cohort 2 - 40 mg (n=12)

    Drug: YN001

Interventions

  • DrugYN001

    YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).

06

What researchers measure

Primary outcomes

  1. To evaluate the maximum plasma concentration (Cmax) of YN001

    Plasma concentration values will be measured to determine Cmax.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  2. To evaluate the time to reach maximum plasma concentration (Tmax) of YN001

    Plasma concentration values will be measured to determine Tmax.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  3. To evaluate the area under the concentration-time curve from time 0 to last measurable concentration (AUC0-t) of YN001

    Plasma concentration values will be used to calculate AUC0-t.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  4. To evaluate the area under the concentration-time curve extrapolated to infinity (AUCinf) of YN001

    Plasma concentration values will be used to calculate AUCinf.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  5. To evaluate the terminal elimination rate constant (λz) of YN001

    Plasma concentration values will be used to estimate λz.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  6. To evaluate the plasma half-life (T1/2) of YN001

    Plasma concentration values will be used to calculate T1/2.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  7. To evaluate the clearance (CL) of YN001

    Plasma concentration values will be used to calculate clearance.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

  8. To evaluate the volume of distribution (Vd) of YN001

    Plasma concentration values will be used to calculate volume of distribution.

    Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

Secondary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and percentage of participants with treatment-emergent AEs and SAEs as assessed by CTCAE v5.0.

    Time frame: Up to 15 days

  2. Incidence of Anti-PEG Antibodies (APA)

    Characterization of anti-PEG antibodies, including the detection rate of pre-existing APAs and the emergence or boosting of treatment-induced APAs.

    Time frame: From pre-dose (D1),Day 5, and Day 8.

  3. Change from Baseline in Laboratory Parameters

    Number and percentage of participants with clinically significant abnormalities in hematology, chemistry, or urinalysis.

    Time frame: Up to 15 days

  4. Change from Baseline in Electrocardiogram (ECG) Parameters

    Number and percentage of participants with clinically significant ECG abnormalities after resting supine ≥5 minutes.

    Time frame: Up to 15 days

  5. Change from Baseline in Vital Signs

    Number and percentage of participants with clinically significant abnormalities in systolic and diastolic blood pressure, pulse, and body temperature.

    Time frame: Up to 15 days

  6. Change from Baseline in Physical Examination Findings

    Number and percentage of participants with clinically significant abnormalities in physical exam findings.

    Time frame: Up to 15 days

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartActual
Nov 18, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07190885
Lead sponsor
Beijing Inno Medicine Co., Ltd.
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Nov 18, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YN001

Start the discussion